{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:04:06Z","timestamp":1789556646957,"version":"build-2803163510"},"reference-count":37,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Endovasc Ther"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Symptomatic infrapopliteal arterial disease often requires challenging endovascular interventions. Percutaneous transluminal angioplasty with stent placement to settle residual stenosis or dissections remains the standard of care for infrapopliteal endovascular intervention. Concerns have been raised about permanent artery rigidification by stainless steel stents. Drug-eluting resorbable scaffolds combine the mechanical support in the acute phase and the delivery of an antirestenotic drug overtime, then fully resorb leaving the vessel free from permanent metallic implant. This study investigated the performance of the Magmaris sirolimus-eluting resorbable magnesium scaffold (RMS) in the management of infra-popliteal, severely diseased leg arteries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This investigator-initiated single-center retrospective study, analyzed all patients with symptomatic peripheral arterial occlusive disease (Rutherford class of symptoms 2\u20135) treated with the Magmaris RMS from 2016 to 2023, for the treatment of infrapopliteal arterial lesions with postangioplasty 50% or more residual stenosis. Technical success, degree of residual stenosis after scaffold implantation, incidences of target lesion primary patency, clinically driven target lesion revascularization (CDTLR), major limb amputation, and all-cause mortality are provided up to 36 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Hundred eleven patients (69.4% male, age 79\u2009\u00b1\u200910) were treated with 141 Magmaris RMS for infrapopliteal lesions (92.3% proximal third of leg). Target lesions had a mean degree of stenosis of 92%, with 52.2% of occlusion and 58.5% of moderate or severe calcification. The mean degree of stenosis after angioplasty remained 60.1%\u2009\u00b1\u200915.8% and fell to 4.8%\u2009\u00b1\u20099.6% after scaffold implantation. Freedom from CDTLR was 95.5%, 93.4%, 90.4%, and 87.9% at 6, 12, 24, and 36\u2009months. Freedom from limb major amputation was 98.2%, 98.1%, 96.4%, and 95.5% and mortality was 7.6%, 10.6%, 24.2%, and 28.8% at 6, 12, 24, and 36\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study suggests that the Magmaris RMS has adequate mechanical properties, drug elution, and resorption time to be safely applied to atherosclerotic infrapopliteal arteries with promising clinical results. These data show that metallic resorbable scaffold may constitute a valuable addition to current option for infrapopliteal arteries management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Impact<\/jats:title>\n                    <jats:p>Resorbable magnesium scaffold (RMS) are an innovation in the treatment of residual stenoses or dissections after angioplasty in the infrapopliteal arteries. They offer mechanical support and drug elution during the healing phase of the artery wall; and then disappear, leaving the artery free of any rigid implant, once the resorption is completed. RMS thus allow the restoration of artery motion and endothelial function. This study provides efficacy and safety information up to 3 years after RMS implantation in severe lesions of the leg arteries and is the largest study in the field of resorbable scaffold for below the knees arteries, as well as the first evaluating magnesium-based alloy scaffolds. It shows immediate and long-term clinical success, well beyond the entire resorption of the RMS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15266028251339356","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:20:47Z","timestamp":1747650047000},"page":"2449-2457","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Sirolimus\u2013Eluting Resorbable Magnesium Scaffold for the Treatment of Patients With Infrapopliteal Arteries Disease: Three-Year Results"],"prefix":"10.1177","volume":"33","author":[{"given":"Adeline","family":"Demierre","sequence":"first","affiliation":[{"name":"Angiology, HFR Fribourg, H\u00f4pital Universitaire et Cantonal, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf P.","family":"Engelberger","sequence":"additional","affiliation":[{"name":"Angiology, HFR Fribourg, H\u00f4pital Universitaire et Cantonal, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hayoz","sequence":"additional","affiliation":[{"name":"Angiology, HFR Fribourg, H\u00f4pital Universitaire et Cantonal, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6499-8090","authenticated-orcid":false,"given":"Daniel","family":"P\u00e9riard","sequence":"additional","affiliation":[{"name":"Angiology, HFR Fribourg, H\u00f4pital Universitaire et Cantonal, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"e_1_3_2_2_2","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman MD","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, et al 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726\u2013e779.","journal-title":"Circulation"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx095"},{"key":"e_1_3_2_4_2","first-page":"655","article-title":"BAD transmission and SAD distribution, a new scenario for critical limb ischemia","volume":"59","author":"Ferraresi R","year":"2018","unstructured":"Ferraresi R, Mauri G, Losurdo F, et al BAD transmission and SAD distribution, a new scenario for critical limb ischemia. J Cardiovasc Surg (Torino). 2018;59:655\u2013664.","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2006.11.022"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.11.055"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2019.02.016"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2008.01.005"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028060130S207"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028211070967"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028231215284"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028211059917"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602815600156"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028231209236"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.03.042"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028221120752"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028211057089"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028211045700"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602820921555"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602820922524"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602818799735"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/15266028221091899"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.29327"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.20.04462-4"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X20977907"},{"key":"e_1_3_2_26_2","article-title":"MOTIV bioresorbable BTK scaffold pilot study preliminary results through 6 months","author":"Rand T.","year":"2022","unstructured":"Rand T. MOTIV bioresorbable BTK scaffold pilot study preliminary results through 6 months. Proceedings of the Leipzig Interventional Course, Leipzig, Germany, June 6\u20139, 2022.","journal-title":"Proceedings of the Leipzig Interventional Course, Leipzig, Germany"},{"key":"e_1_3_2_27_2","article-title":"Angiographic and clinical outcomes of the thin-strut MAGNITUDE bioresorbable scaffold in patients with below-the-knee arterial disease: early results from the RESOLV I Trial","author":"Secemski E.","year":"2023","unstructured":"Secemski E. Angiographic and clinical outcomes of the thin-strut MAGNITUDE bioresorbable scaffold in patients with below-the-knee arterial disease: early results from the RESOLV I Trial. TCT 2023, San Francisco, CA, October 25, 2023.","journal-title":"TCT"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305637"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2020.04.006"},{"key":"e_1_3_2_30_2","first-page":"616","article-title":"Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: long-term data of the BIOSOLVE-II first-in-man trial at 5 years","volume":"69","author":"Haude M","year":"2021","unstructured":"Haude M, Toelg R, Lemos PA, et al Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: long-term data of the BIOSOLVE-II first-in-man trial at 5 years. Cardiovasc Revasc Med. 2021;69:616.","journal-title":"Cardiovasc Revasc Med"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/1526602820931488"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.19.04049-5"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.07.099"},{"key":"e_1_3_2_34_2","first-page":"100964","article-title":"Evaluation of an infrapopliteal drug-eluting resorbable scaffold, design methodology for the LIFE-BTK Randomized Controlled Trial","volume":"31","author":"Varcoe RL","year":"2023","unstructured":"Varcoe RL, Parikh SA, DeRubertis BG, et al Evaluation of an infrapopliteal drug-eluting resorbable scaffold, design methodology for the LIFE-BTK Randomized Controlled Trial. J Soc Cardiovasc Angiogr Interv. 2023;31:100964.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"e_1_3_2_35_2","volume-title":"Paper presented at: the USGG Congress the November 7, 2024","author":"Rand T.","unstructured":"Rand T. The MOTIV single arm pilot study preliminary results. Paper presented at: the USGG Congress the November 7, 2024; Basel, Switzerland."},{"key":"e_1_3_2_36_2","volume-title":"Paper presented at: the ISET congress, Hollywood Florida, February 5, 2025","author":"The RESOLV TRIAL, preliminary results","unstructured":"The RESOLV TRIAL, preliminary results. Paper presented at: the ISET congress, Hollywood Florida, February 5, 2025."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-21-00651"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-23-00326"}],"container-title":["Journal of Endovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251339356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15266028251339356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15266028251339356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:14:59Z","timestamp":1789553699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15266028251339356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/15266028251339356"],"URL":"https:\/\/doi.org\/10.1177\/15266028251339356","relation":{},"ISSN":["1526-6028","1545-1550"],"issn-type":[{"value":"1526-6028","type":"print"},{"value":"1545-1550","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}